Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer and the leading cause of cancer deaths worldwide.1 Despite immunotherapy, radiotherapy, and chemotherapy advances, treatment outcomes remain unsatisfactory.2 Thus, prognostic models that accurately predict patient prognosis and guide individualized treatment are desperately needed. SUMOylation, a reversible post-translational modification, is a crucial molecular regulatory mechanism that affects tumor progression.3 However, the role of sumoylation-related lncRNAs (SR-lncRNAs) in LUAD has not been explored. This study aimed to construct and validate an SR-lncRNAs signature for predicting LUAD prognosis, tumor immune microenvironment, and therapeutic sensitivity.